| Kallikreins are involved in an miRNA network that contributes to prostate cancer progression S Samaan, Z Lichner, Q Ding, C Saleh, J Samuel, C Streutker, GM Yousef Biological Chemistry 395 (9), 991-1001, 2014 | 38 | 2014 |
| miRNAs dysregulated in association with Gleason grade regulate extracellular matrix, cytoskeleton and androgen receptor pathways Z Lichner, Q Ding, S Samaan, C Saleh, A Nasser, S Al‐Haddad, ... The Journal of pathology 237 (2), 226-237, 2015 | 34 | 2015 |
| Kallikrein-related peptidase 5 induces miRNA-mediated anti-oncogenic pathways in breast cancer KG Sidiropoulos, NMA White, A Bui, Q Ding, P Boulos, G Pampalakis, ... Oncoscience 1 (11), 709, 2014 | 33 | 2014 |
| Association of quality-of-life outcomes in cancer drug trials with survival outcomes and drug class JN Samuel, CM Booth, E Eisenhauer, M Brundage, SR Berry, B Gyawali JAMA oncology 8 (6), 879-886, 2022 | 30 | 2022 |
| Routine surveillance of chemotherapy toxicities in cancer patients using the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) TQ Wang, JN Samuel, MC Brown, A Vennettilli, H Solomon, L Eng, ... Oncology and Therapy 6, 189-201, 2018 | 12 | 2018 |
| Anticoagulation prophylaxis in asparaginase-based therapy in adults with acute lymphoblastic leukemia H Sibai, U Falcone, AD Law, N Sakurai, L Saini, TQ Wang, A Stessman, ... Blood 128 (22), 1453, 2016 | 2 | 2016 |
| Safety of using escalated doses of enoxaparin prophylaxis in adults with acute lymphoblastic leukemia receiving asparaginase-based intensification therapy. HA Sibai, JT Seki, T Wang, L Saini, A Stessman, J Samuel, N Sakurai, ... Journal of Clinical Oncology 34 (7_suppl), 141-141, 2016 | 1 | 2016 |
| Does Venous Thromboembolism Prophylaxis Policy Have Any Impact on Clot Risk Reduction in Hospitalized Solid Tumor Patients at Princess Margaret Cancer Centre: A Longitudinal Study? A Xu, T Wang, EG Atenafu, H Sibai, AD Law, K Japs, J Samuel, T Vather, ... Blood 130, 5651, 2017 | | 2017 |
| Pharmacovigilance Data from Systematic Patient Reported Outcome (PRO) Tools Versus Usual Clinician Interactions: Are Cancer Patients Reporting Toxicity Data To Their Health … JN Samuel, TQ Wang, A Perez-Cosio, MC Brown, A Vennettilli, N Cheng, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 24, 448-448, 2015 | | 2015 |
| Abstract| PDF| Full Text| Supplementary Materials| Order a Reprint| https://doi. org/10.18632/oncoscience. 91 KG Sidiropoulos, NMA White, A Bui, Q Ding, P Boulos, G Pampalakis, ... | | |
